JP2017508442A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508442A5
JP2017508442A5 JP2016546862A JP2016546862A JP2017508442A5 JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5 JP 2016546862 A JP2016546862 A JP 2016546862A JP 2016546862 A JP2016546862 A JP 2016546862A JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5
Authority
JP
Japan
Prior art keywords
genes listed
derivative
mdm2i
salt
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/051157 external-priority patent/WO2015108175A1/en
Publication of JP2017508442A publication Critical patent/JP2017508442A/ja
Publication of JP2017508442A5 publication Critical patent/JP2017508442A5/ja
Pending legal-status Critical Current

Links

JP2016546862A 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー Pending JP2017508442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927310P 2014-01-14 2014-01-14
US61/927,310 2014-01-14
PCT/JP2015/051157 WO2015108175A1 (en) 2014-01-14 2015-01-13 Gene signatures associated with sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017508442A JP2017508442A (ja) 2017-03-30
JP2017508442A5 true JP2017508442A5 (show.php) 2018-02-08

Family

ID=52432889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546862A Pending JP2017508442A (ja) 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー

Country Status (4)

Country Link
US (1) US20160333419A1 (show.php)
EP (1) EP3094746A1 (show.php)
JP (1) JP2017508442A (show.php)
WO (1) WO2015108175A1 (show.php)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
WO2012121361A1 (ja) 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス,インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TWI804010B (zh) * 2015-08-03 2023-06-01 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
TW201722428A (zh) * 2015-10-23 2017-07-01 第一三共股份有限公司 用於治療急性骨髓性白血病(aml)之醫藥組成物及對有此需要者進行急性骨髓性白血病治療之方法
TW202332444A (zh) 2015-10-23 2023-08-16 日商第一三共股份有限公司 用於治療癌症之醫藥組成物
CN106512009B (zh) * 2016-10-28 2019-10-11 武汉大学 Ph同源域家族a成员3(phlda3)在治疗心肌肥厚中的应用
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
JP7638527B2 (ja) * 2019-05-23 2025-03-04 国立大学法人大阪大学 性ホルモン非感受性greb1陽性腫瘍の治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020502A2 (en) * 2012-07-31 2014-02-06 Novartis Ag Markers associated with human double minute 2 inhibitors
CN105378112B (zh) * 2013-07-03 2020-10-13 豪夫迈·罗氏有限公司 用于将用MDM2拮抗剂进行患者癌症治疗个人化的基于mRNA的基因表达

Similar Documents

Publication Publication Date Title
JP2017508442A5 (show.php)
CN112930569B (zh) 无细胞dna中的微卫星不稳定性检测
Ropers On the future of genetic risk assessment
Desai et al. Next‐generation sequencing: ready for the clinics?
Bilke et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
JP2013127477A5 (show.php)
Vos et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
EP4574992A3 (en) Combinatorial dna screening
JP2017523810A5 (show.php)
Noviello et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
JP2016532689A5 (show.php)
JP2017512491A5 (show.php)
JP2012501452A5 (show.php)
JP2017532959A5 (show.php)
JP2011528903A5 (show.php)
EP3867403A1 (en) Method for quantifying molecular activity in cancer cells of a human tumour
JP2017509351A5 (show.php)
Ju et al. Identification of a miRNA-mRNA network associated with lymph node metastasis in colorectal cancer
US20150071946A1 (en) Tumor-specific retrotransposon insertions
RU2009127735A (ru) Определение предрасположенности к раку путем идентификации генотипических комбинаций специфичных вариантов генов cyp1b1, brca2 и снек2
KR20170072685A (ko) 삼중음성유방암의 아형 분류 방법
CN111480079A (zh) 疾病蛋白质组蛋白质阵列及其应用
Huang et al. Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing
Flannery et al. Improved PCR diagnostics using up-to-date in silico validation: an F-gene RT-qPCR assay for the detection of all four lineages of peste des petits ruminants virus
RU2621161C1 (ru) Способ диагностики гликогеновой болезни IXa типа у детей с использованием технологии секвенирования нового поколения